Statement: Most patients in cohort 1 of the primary trial died of unknown causes.
Primary_evidence: Adverse Events 1:   Total: 7/26 (26.92%)   Febrile neutropenia 1/26 (3.85%)   Neutropenia 0/26 (0.00%)   Thrombocytopenia 0/26 (0.00%)   Cardiac failure congestive 0/26 (0.00%)   Extrasystoles 0/26 (0.00%)   Nausea 1/26 (3.85%)   Abdominal pain 0/26 (0.00%)   Constipation 0/26 (0.00%)   Gastrointestinal haemorrhage 0/26 (0.00%)   Death - unknown cause 1/26 (3.85%)   Thrombosis in device 0/26 (0.00%) Adverse Events 2:   Total: 5/10 (50.00%)   Febrile neutropenia 0/10 (0.00%)   Neutropenia 0/10 (0.00%)   Thrombocytopenia 1/10 (10.00%)   Cardiac failure congestive 0/10 (0.00%)   Extrasystoles 0/10 (0.00%)   Nausea 0/10 (0.00%)   Abdominal pain 0/10 (0.00%)   Constipation 0/10 (0.00%)   Gastrointestinal haemorrhage 0/10 (0.00%)   Death - unknown cause 0/10 (0.00%)   Thrombosis in device 0/10 (0.00%)